← All trials
NCT05658510
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2022
- Primary completion
- Mar 30, 2024
- Completion date
- Mar 30, 2024
- First posted
- Dec 20, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 450
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BioXcel Therapeutics IncLead sponsor
- Worldwide Clinical TrialsCollaborator
- BioXcel Therapeutics IncStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.